Hematologic Oncology

Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.

Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.

“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.

The updated NCCN guidelines for myeloproliferative neoplasms recommend rusfertide as a Category 1 option across both low- and high-risk polycythemia vera.

"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

At SOHO 2026, Jasmine Zain, MD, discussed communicating the FDA’s boxed warning for secondary malignancies post–CAR T-cell therapy to patients.

The phase 3 TAK-226-3001 trial will evaluate elritercept vs epoetin alfa for anemia in lower-risk myelodysplastic syndromes.

Data from the phase 2 PARADIGM trial may support the use of less toxic, more gentle therapies for patients with acute myeloid leukemia.

Ruben Mesa, MD, discusses the FDA approval of ropeginterferon alfa-2b-njft, the first new essential thrombocythemia therapy in nearly 30 years.

Ropeginterferon alfa may play an important role in future combination strategies in essential thrombocythemia, said Ruben Mesa, MD, FACP.

The FDA approval of ropeginterferon alfa-2b may lead to longer and better outcomes in essential thrombocythemia, according to Ruben Mesa, MD, FACP.

Data from the phase 3 SENTRY trial support the supplemental new drug application for selinexor plus ruxolitinib in patients with myelofibrosis.

Data from the phase 3 SURPASS ET trial supported the approval of ropeginterferon alfa-2b-njft for those with essential thrombocythemia.

Results from the phase 3 VERIFY trial led to the approval of rusfertide in polycythemia vera.

In a real-world setting, venetoclax plus a hypomethylating agent produced a median overall survival of 13.0 months in newly diagnosed acute myeloid leukemia.

Andrew Evens, DO & Joanna Rhodes, MD, on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across NJ.

The FDA cited outstanding manufacturing observations while raising no concerns about clinical data, bioequivalence, or stability in its CRL.

The phase 2 SANRECO trial met its primary end point, with 88% of this polycythemia vera population achieving a response with divesiran vs 19% with placebo.

Updated results from the phase 2 ELIANA trial support tisa-cel as definitive therapy for pediatric and young adult patients with relapsed/refractory B-ALL.

Pirtobrutinib plus venetoclax/rituximab reduced the risk of progression or death by 45% among those with CLL in the phase 3 BRUIN CLL-322 trial.

Transplant-associated thrombotic microangiopathy GVHD are related, but distinct consequences of endothelial injury after allogeneic HCT.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, predicts operational challenges as CAR T-cell therapy expands to non-oncology indications.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, says equitable access to CAR T-cell therapy depends on partnership, not just center certification.

Clinicians “still don’t have the answer” on true toxicity thresholds, says Tiba Al Sagheer, PharmD, BCOP, BCACP, on CAR T-cell toxicity management.